Panel Discussion: Aligning with Physicians, Payers, & Regulators to Strengthen an Integrated Roadmap for Drug– Diagnostic Value & Access

• What lessons from HER2, EGFR, and PD-L1 can we apply today, and what are the biggest barriers we see today in drug-diagnostic co-development? 
• When Rx-Dx don’t launch together, what are the downstream consequences for physicians, patients, and payers, and how can these be prevented? 
• What pitfalls must be avoided as we move toward more complex multimodal and AI-driven diagnostics?

Speakers:

Jonathan Beer

Senior Director, Precision Medicine

Bristol Myers Squibb

EK Kim

Head of Global Commercial Biomarkers & Diagnostics

Amgen

Jill Walker

Founder

Beacon Scientific Consulting